Century Therapeutics Hits New 52-Week High at $2.95

Century Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 2.95 on March 9, 2026. This achievement marks a notable point for the microcap company, which operates within the Pharmaceuticals & Biotechnology industry. Despite this recent uptick, Century Therapeutics has experienced a 1-year performance decline of 12.24%, contrasting sharply with the S&P 500's gain of 17.78% over the same period. The company's market capitalization stands at USD 370 million, reflecting its microcap status. Financial metrics indicate that Century Therapeutics is currently loss-making, with a negative return on equity of -8.65% and a debt-to-equity ratio of -0.73. The stock's price-to-book ratio is recorded at 2.10, while the company does not offer a dividend yield. This new high underscores the stock's volatility and the dynamic nature of the biotechnology sector, as investors and market participants continue to monitor its performance closely.